[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501264":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":24,"armGroups":36,"interventions":49,"overallOfficials":59,"centralContacts":63,"locations":69,"responsibleParty":87,"collaborators":24,"id":90,"slug":24,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":24,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":24,"enrollmentInfo":98,"targetDuration":24,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":24,"overallStatus":72,"whyStopped":24,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Mayo Clinic","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of bladder spasm","Number of subjects to experience bladder spasms","Post-operative, approximately 1 hour",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"Incidence of bladder spasm above moderate grade","Number of subjects to experience bladder spasms above moderate grade","Post-operative, approximately 4 hours",{"measure":19,"description":20,"timeFrame":17},"Treatment for bladder spasms","Number of subjects requiring treatment for bladder spasms",{"measure":22,"description":23,"timeFrame":17},"Patient satisfaction","Assessed using a seven-point Likert scale where 1=strongly dissatisfied, 2=moderately dissatisfied, 3=slightly dissatisfied, 4=neutral, 5=slightly satisfied, 6=moderately satisfied, 7=extremely satisfied",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":24,"primaryPurpose":28,"observationalModel":24,"timePerspective":24,"maskingInfo":29},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":30,"maskingDescription":24,"whoMasked":31},"QUADRUPLE",[32,33,34,35],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[37,43],{"label":38,"type":39,"description":40,"interventionNames":41},"Magnesium Group","EXPERIMENTAL","Subjects having urology surgery per standard of care will receive intravenous magnesium during the surgery.",[42],"Drug: Magnesium",{"label":44,"type":45,"description":46,"interventionNames":47},"Placebo Group","PLACEBO_COMPARATOR","Subjects having urology surgery per standard of care will receive intravenous placebo during the surgery.",[48],"Drug: Placebo",[50,55],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":24},"DRUG","Magnesium","Intravenous infusion, load 50 mg\u002FKg with infusion of 15 mg\u002FKg\u002Fhour",[38],{"type":51,"name":56,"description":57,"armGroupLabels":58,"otherNames":24},"Placebo","Equivalent volume of normal saline",[44],[60],{"name":61,"affiliation":5,"role":62},"Gregory Nuttall, MD","PRINCIPAL_INVESTIGATOR",[64],{"name":65,"role":66,"phone":67,"phoneExt":24,"email":68},"Tami Krpata","CONTACT","507-422-5768","krpata.tami@mayo.edu",[70],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Mayo Clinic in Minnesota","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":79,"coordinates":80},"Point",[81,82],-92.4699,44.02163,{"lat":82,"lon":81},[85],{"name":86,"role":66,"phone":24,"phoneExt":24,"email":24},"Holly Carlson",{"type":62,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Gregory A Nuttall","Principal Investigator","100501264",false,"NCT05806996","A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures","Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures","Inclusion Criteria:\n\n\\- Be undergoing a bladder invasive procedure with or without planned urinary catheter on Mayo Clinic Gonda 7 Outpatient Procedure Center.\n\nExclusion Criteria:\n\n* Are unable to grant informed consent or comply with study procedure.\n* Allergy or known sensitivity to magnesium or Renacidin.\n* Expected or high risk of bladder extravasation.\n* Ongoing atrial fibrillation prior to surgery.\n* Are undergoing emergency surgery.\n* Are pregnant.\n* Known hypermagnesemia.\n* Patients with neuromuscular weakness (e.g., Myasthenia gravis) due to magnesium's muscle weakening effect.\n* Patients with myocardial compromise or cardiac conduction defects because of magnesium's anti-inotropic effects.\n* Patients with renal insufficiency, glomerular filtration rate less than 30, since Magnesium is eliminated by the kidneys resulting in exaggerated rise in serum magnesium.\n* Patients with concomitant use of a calcium channel blocker since magnesium sulfate could act synergistically to suppress muscular contractility.","ALL","18 Years",{"count":99,"type":100},120,"ESTIMATED","INTERVENTIONAL",[103],"PHASE2","This research is being done to find out whether intravenous magnesium is effective in the treatment of bladder spasms after urologic surgery.",[106],"Bladder Spasms","2026-06-25",{"date":109,"type":110},"2026-06-29","ACTUAL",{"date":112,"type":110},"2023-07-31",{"date":114,"type":100},"2026-12-31",{"name":5,"class":6},1]